Business Wire

HANSHOW

8.11.2021 07:27:11 CET | Business Wire | Press release

Share
Hanshow Announces New AI Camera-Driven Solutions in China Developed in Collaboration With Microsoft and Sony Semiconductor Solutions

At the 2021 China International Import Expo (CIIE), Hanshow has announced a commercial AI camera-driven retail solution, developed through a collaboration with Microsoft and Sony Semiconductor Solutions Corporation (Sony). This solution combines Sony’s intelligent vision sensor IMX500, the world’s first image sensor equipped with AI functionality, with Microsoft Azure and its AI capabilities to achieve AI processing on edge. As part of the Partner Enablement Program through Microsoft AI & IoT Insider Labs, Microsoft Global ISV Hanshow continues to upgrade its intelligent solution to better serve its global customers especially in the retail industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211107005144/en/

In a busy retail setting, staff are often unable to complete timely and accurate monitoring of product shelf status. This results in products being out-of-stock, improperly arranged, lost sales, unsatisfied customers, and unattractive store appearance. Meanwhile, customer flow analysis is crucial for retailers to better understand customer behavior in their stores including traffic, visited areas, customer paths, dwell time and loyalty.

Hanshow’s AI retail solution monitors out-of-stock occurrences along with product volume status, customer traffic flows, sales levels, and other store information. This not only allows for real time out-of-stock notifications, but also stores and analyzes data over time to help managers optimize operations and displays.

This upgraded AI retail solution involves Hanshow’s AI calculations (product recognition), digital advertising technology with media content at the shelf based on the Azure AI and IoT platform with data collection and analysis from Sony’s IMX 500 intelligent vision sensor. This also opens new sales opportunities for retailers and creates more customer behavior data to help drive targeted advertising.

The sensor outputs metadata (semantic information belonging to image data) instead of image information, that helps in reducing data traffic and addressing privacy concerns by not collecting personal information. A similar Hanshow solution is already in use at supermarket settings. One major supermarket chain saw a near 50% reduction in out-of-stock time by using similar AI technology.

This solution and three-party collaboration was born out of Microsoft’s Partner Enablement Program which enriches existing tech ecosystems by recruiting qualified partners with experiences, sales and marketing resources to accelerate their time to market through the Microsoft AI & IoT Insider Labs.

Hanshow’s experience in global retail markets, combined with the technological support from Microsoft and Sony “can accelerate co-innovation initiatives to better serve the rapidly changing and diversified retail industry, helping retailers to be more agile and profitable. We are also exploring application of this solution in manufacturing and other industries together with Microsoft and Sony.” said Shiguo Hou, the CEO of Hanshow.

About Hanshow

Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. As an innovation leader in the industry, Hanshow is dedicated to offering its global customers a series of world-class customized IoT touchpoints and digital store solutions. Hanshow’s intelligence-enabled platforms and systems deliver customer-centric insights, helping retailers streamline operations and providing various solutions to support optimal pricing strategies to offer consumers a more personalized experience. Hanshow currently serves over 20,000 stores in more than 50 countries. Contact Hanshow: https://www.hanshow.com/Form.html

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye